Radiotherapy in the treatment of localised non Hodgkin's lymphoma. With the routine use of laparotomy staging, common patterns of spread of lymphoma were defined. The inability of aggressive conventional chemotherapy to provide more than a few patients with advanced follicular low-grade lymphoma with durable complete remissions led to pessimism about the curative potential of any treatment in these histologies.
Current clinical trials of high-dose chemotherapy with transplantation of bone marrow or peripheral blood stem cells may offer the prospect of more durable remissions and, it is hoped, provide indefinite freedom from relapse in a proportion of cases.
Which patients with relapsed non-Hodgkin's lymphoma benefit from high dose therapy and hematopoietic stem cell transplantation? The therapeutic principles currently applicable to the treatment of advanced low-grade lymphoma may sometimes be applied indiscriminately to the management of patients with early-stage disease. It has been suggested that treatment does not alter the natural history of the illness at any stage, and that therapy is always palliative in nature.
This approach may deny some patients a chance to eradicate clinical manifestations of the disease for the remainder of their lives. Currently, it is unknown whether deferred treatment for early-stage patients is safe or if some patients with initially localized disease may develop incurable disseminated disease that could have been prevented by prompt local irradiation.
The results of long-term follow-up of patients with stage I and II low-grade follicular lymphomas treated at Stanford University have recently been reviewed to evaluate the curative potential of radiation therapy.
Is radiotherapy curative for stage I and II low grade follicular lymphoma? Evidence for the effectiveness of chemotherapy combined with radiation therapy in localized low-grade lymphoma will also be reviewed. Bienvenue sur EM-consulte, la référence des professionnels de santé.
Br regimen in follicular lymphoma young
Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite. Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles. Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.
Nous adhérons aux principes de la charte HONcode. Valider Annuler. Médecine générale Médecine interne Médecine légale Médecines complémentaires Neurologie, neuropsychologie Ophtalmologie Oto-rhino-laryngologie Pédiatrie Pharmacologie, Thérapeutique.
Biologie, Bactériologie, maladies infectieuses Cancérologie Cardiologie, Médecine vasculaire Chirurgie générale et digestive Chirurgie orthopédique, Traumatologie Chirurgie plastique Chirurgie, autres Dermatologie, Vénérologie Dictionnaires et lexiques. Ann Oncol ;21 Suppl 5:v Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
J Clin Oncol Sep 20;27 27 J Clin Oncol ; Peripheral T-cell lymphoma unspecified PTCL-U : a new prognostic model from a retrospective multicentric clinical study.
Blood Apr 1; 7 J Clin Oncol ;31 2 Hasenclever D, Diehl V. N Engl J Med ; Confirmation of the mantle-cell lymphoma international prognostic indes in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol May 1;32 13 J Clin Oncol Apr 1;32 10 J Clin Oncol ;30 27 Haematologica ;97 2 Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy PRIMA : a phase 3, randomised controlled trial.
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Ann Oncol ; 11 suppl1: Blood March 1; Follicular lymphoma international prognostic index. N Engl J Med. Tumor-associated macrophages predict outcomes in classic Hodgkin lymphoma:a correlative study from the E Intergroup trial. Blood ; 16 Blood ; J Clin Oncol Revised response criteria for malignant lymphoma.
J Clin Oncol. Cheson BD, Role of functional imaging in the management of lymphoma. J Clin Oncol,29 The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
Gallamini A. Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica ; Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Report on the first international workshop on interim-PET scan in lymphoma.
Leuk Lymphoma. Report on the third international workshop on Interim Positron Emission Tomography in lymphoma held in Menton, France, 26 — 27 September and Menton consensus.
Arakelyan N et al.
Cancer ; : Annals of Oncology —, State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol ;9 8 J Clin Oncol 30, suppl ;abstr Bloodabstr German Hodgkin Lymphoma Study Group. N Engl J Med ; J Clin Oncol ; Blood ;, abstr Ann Oncol,21 Suppl 5:v Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma HD15 trial : a randomised, open-label, phase 3 non-inferiority trial.
Radiother Oncol ; J Clin Oncol,23 J Clin Oncol Feb 20;31 6 Herbst C, Rehan FA, Brillant C, et al: Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. J Clin Oncol,Hodgkin lymphoma in older patients:challenges and opportunities to improve outcomes. Hematol Oncol,31 Suppl